INSP
Inspire Medical Systems, Inc.
INSP has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over INSP overall, supported by stronger fundamentals and stronger modeled upside.
INSP Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Healthy | |
| Healthy | |
| Strong |
INSP's profitability, cash flow and balance sheet are currently healthy, but its revenue is under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
INSP PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 12x | $39.83 | -34% |
| Current | 18x | $60.54 | — |
| Forward | 43x | $60.54 | — |
| Fair | 58x | $194 | +220% |
| Expensive | 173x | $579 | +857% |
Historical ranges are pointers, not guarantees.
INSP's PE is in its cheap range at 18x. On analysts' estimates for next year's earnings, today's price would be 43x, in its fair range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over INSP in the historical PE scenario, which offers more potential upside but is not a forecast.
INSP Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect INSP's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over INSP on the outlook, with more favorable valuation and revenue expectations.
INSP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.41 | -58% |
| Q3 2026 | $3.35 | +125% |
| Q2 2026 | $4.53 | +159% |
| Q1 2026 | $4.40 | +101% |
| Q4 2025 | $4.89 | +179% |
| Q3 2025 | $1.49 | +37% |
| Q2 2025 | $1.75 | +775% |
| Q1 2025 | $2.19 | +$2.72 |
| Q4 2024 | $1.75 | +$2.47 |
INSP has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
INSP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $206.7M | -7.9% |
| Q2 2026 | $200.6M | -7.6% |
| Q1 2026 | $204.6M | +1.6% |
| Q4 2025 | $269.1M | +12% |
| Q3 2025 | $224.5M | +10% |
| Q2 2025 | $217.1M | +11% |
| Q1 2025 | $201.3M | +23% |
| Q4 2024 | $239.7M | +25% |
INSP's revenue has held roughly level: $207M last quarter, down 7.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -14% | -18 points |
| Q2 2026 | -0.3% | +1.3 points |
| Q1 2026 | -0.6% | +0.2 points |
| Q4 2025 | 17% | +3.8 points |
| Q3 2025 | 4.3% | -2.8 points |
| Q2 2025 | -1.5% | -4.1 points |
| Q1 2025 | -0.7% | +8.5 points |
| Q4 2024 | 13% | +8.5 points |
INSP's operating margin was −14% last quarter, down 18 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over INSP on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over INSP on profitability, with a higher operating margin.
INSP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $38.9M | -33% |
| Q2 2026 | $14.1M | +$20.4M |
| Q1 2026 | $3.1M | +$18.2M |
| Q4 2025 | $41.8M | -33% |
| Q3 2025 | $58.1M | +31% |
| Q2 2025 | -$6.3M | +$6.2M |
| Q1 2025 | -$15.1M | -$12.3M |
| Q4 2024 | $62.2M | +573% |
INSP generated $98M in free cash flow over the past year, about the same as the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over INSP on cash flow, with more consistent year-over-year improvement.
INSP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -11.5K shares |
| 1 year | -2.3% | -671K shares |
| 3 years | -1.5% | -437K shares |
| 5 years | +6% | +1.6M shares |
| Available history | +22% | +5.1M shares |
INSP has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $50M |
| Q3 2025 | $50M |
| Q2 2025 | — |
| Q1 2025 | $75M |
INSP spent $50M buying back its own shares over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
INSP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -5.6x | Net Cash |
| Q2 2026 | -1.8x | Net Cash |
| Q1 2026 | -1.5x | Net Cash |
| Q4 2025 | -1.6x | Net Cash |
| Q3 2025 | -2.3x | Net Cash |
| Q2 2025 | -2.1x | Net Cash |
| Q1 2025 | -0.9x | Net Cash |
| Q4 2024 | -3.5x | Net Cash |
INSP has the edge over OSCR on leverage, with a lower net debt burden relative to earnings.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
INSP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.7 | Neutral |
| Stochastic | 44.4 | Neutral |
INSP's weekly RSI is 47 (neutral) and its Stochastic is 44 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
INSP PE vs Healthcare Sector
| Metric | INSP | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 30% below |
| PE % | 32 | 29 | 3 pts above |
INSP is trading at 18x earnings, a 30% discount to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over INSP on valuation relative to its sector.
INSP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $67.7 | 11% below |
| 20 week MA | $62.2 | 2.7% below |
| 50 week MA | $64.8 | 6.5% below |
| 100 week MA | $99.3 | 39% below |
| 200 week MA | $156.2 | 61% below |
INSP is in a downtrend: it's below all five of its weekly moving averages, and 61% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over INSP on trend strength, trading above more of its moving averages.
INSP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $74.2 | $190.7 | +157% |
| 2021 | $190.7 | $239.2 | +25% |
| 2022 | $239.2 | $257.5 | +7.7% |
| 2023 | $257.5 | $203.4 | -21% |
| 2024 | $203.4 | $188.5 | -7.3% |
| 2025 | $188.5 | $95.5 | -49% |
| 2026 YTD | $95.5 | $60.5 | -37% |
INSP has finished three years in a row lower, and it's down 37% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over INSP on returns for 2026, with the stronger performance.